Filing Flows › Skinvisible (SKVI) › Q1 2026 › vs Q1 2025
Skinvisible (SKVI) Q1 2026 vs Q1 2025 (year over year)
Skinvisible's revenue rose $0 (0%) from $5K in Q1 2025 to $5K in Q1 2026.
Skinvisible, Q1 2026: revenue $5K (0% year over year), net loss $267K, operating cash flow −$1K. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $5K | $0 | 0% |
| Net loss | $267K | $281K | −$14K | -5% |
| Costs & expenses | $272K | $286K | −$14K | -5% |
| Operating costs | $131K | $145K | −$14K | -10% |
| Interest & other, net | $141K | $141K | $93 | +0.1% |
| Cost of revenue | $0 | $0 | $0 | — |
| SG&A | $126K | $140K | −$14K | -10% |
| Other operating costs | $5K | $5K | $67 | +1% |
| Operating cash sources | $267K | $281K | −$14K | -5% |
| Depreciation & amortization | $5K | $5K | $67 | +1% |
| Working capital & other | $261K | $244K | $17K | +7% |
| Cash used in operations | $1K | $32K | −$31K | -97% |
| Net loss absorbed | $267K | $281K | −$14K | -5% |
Questions
How much did Skinvisible's revenue grow year over year in Q1 2026?
Skinvisible's revenue rose $0 (0%) from $5K in Q1 2025 to $5K in Q1 2026.